Robo
Enterprise-grade AI for complex asset search and evaluation, specifically for biopharma opportunities.
Website: https://robo.tech/
Cover Block
Open sources
| Name | Robo |
| Tagline | Enterprise-grade AI for complex asset search and evaluation, specifically for biopharma opportunities. |
| Headquarters | Santa Monica, CA, US [LinkedIn, retrieved 2026] |
| Business Model | SaaS |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Links
Open sources
- Website: https://robo.tech/
- LinkedIn: https://www.linkedin.com/company/roboresearch
What an Investor Needs First
Open sources
Robo is building enterprise-grade AI to automate the complex search and evaluation of external assets for biopharma companies, a process currently mired in manual research and static databases [Robo.tech, retrieved 2026]. The company's core proposition is timely, addressing a clear operational bottleneck: the sheer volume of scientific data, from over 100 million primary sources, has outpaced the capacity of traditional research teams [Robo.tech, retrieved 2026]. Its platform allows users to define nuanced objectives in natural language, which are then executed by tailored AI agents that score assets with claimed PhD-level rigor, aiming to close a critical gap in the market for dynamic, automated due diligence.
The founding team, Braydon Moreno and David Dimeo, is identified in third-party databases, though their publicly visible professional backgrounds are not directly in biopharma or AI research [Tracxn, retrieved 2026] [CB Insights, retrieved 2026]. Moreno's LinkedIn profile shows involvement in metal fabrication and a separate 3D printing venture, while Dimeo is linked to a digital retailing agency, suggesting entrepreneurial experience but in different domains [LinkedIn: Braydon Moreno, retrieved 2026] [LinkedIn: David Dimeo, retrieved 2026]. The company operates as a SaaS business from Santa Monica, California, but its funding history, current capitalization, and commercial traction are not publicly disclosed, presenting a significant information gap for investors.
Over the next 12-18 months, the key watchpoints will be the emergence of validated customer deployments, the publication of specific traction metrics, and any formal funding announcements. The primary risk to monitor is whether the founders can translate their general entrepreneurial experience into credible domain expertise and sales execution within the highly specialized and regulated biopharma sector.
Partially corroborated -- Product claims are sourced from the company's website; founder identities are listed in databases but lack corroborating primary sources; funding and metrics are unconfirmed.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | SaaS |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Inside the Company
Open sources
Robo is an enterprise AI company based in Santa Monica, California, focused on automating complex asset search and evaluation for the biopharma sector [Robo.tech, retrieved 2026]. The company's public presence is anchored by its website and a LinkedIn profile, which lists its headquarters and a team size of 2-10 employees [LinkedIn, retrieved 2026].
The founding team consists of Braydon Moreno and David Dimeo, who are identified as co-founders across multiple corporate databases [Tracxn, retrieved 2026][CB Insights, retrieved 2026]. A key point of analysis is the potential for brand confusion, as the founders are also associated with other entities using the "Robo" name. Braydon Moreno is listed as the CEO and co-founder of Robo 3D, a 3D printer manufacturer [Crunchbase, retrieved 2026][ideamensch.com, retrieved 2026]. David Dimeo is identified as a co-founder of Robo Retail, LLC, a digital retailing agency [The Org: David DiMeo, retrieved 2026][Success.ai: David Dimeo, retrieved 2026]. This suggests the founders may have a history of launching ventures under a shared brand umbrella, or that the name is a common element across distinct, unrelated businesses. The specific entity at robo.tech appears to be a separate undertaking focused on biopharma AI, distinct from the robotics startup RoboForce, which raised a $10 million round in early 2025 [Robotics Tomorrow, January 2025].
Public milestones for Robo are limited to its digital footprint. The company has established its core product narrative online, emphasizing its capability to process over 100 million primary data sources for biopharma research [Robo.tech, retrieved 2026]. No public funding rounds, accelerator participation, or specific launch dates have been confirmed through primary sources.
Partially corroborated -- Company location and founding team names are corroborated by multiple databases, but key details like founding date and corporate structure are not publicly verified.
Under the Hood
Reported and inferred
Robo's platform is positioned as a specialized research automation engine for biopharma, built to address the specific challenge of evaluating external assets like drug candidates or technologies. The core workflow, as described on the company's website, begins with a user outlining their objectives in natural language, which the system then converts into tailored AI agents for search and evaluation [Robo.tech, retrieved 2026]. These agents are claimed to research across a proprietary database of over 100 million primary data sources, including publications, trial registries, patents, and conference abstracts [Robo.tech, retrieved 2026]. The evaluation step is framed as applying "PhD-level rigor" to score each asset against the user's custom criteria, with the system designed to incorporate user feedback instantly to refine subsequent results [Robo.tech, retrieved 2026].
The platform's architecture appears to be a SaaS application, with the AI agents functioning as the primary user-facing interface for a complex backend data processing pipeline. The technology stack is not publicly detailed, but the product's reliance on processing vast, unstructured datasets suggests significant investment in data ingestion, normalization, and natural language understanding models. A key differentiator claimed is the end-to-end automation of what the company calls "nuanced, mission-critical research," moving beyond static databases or generic AI tools that may hallucinate or cover only narrow data slices [Robo.tech, retrieved 2026]. The system also promises ongoing updates, refreshing asset profiles as new data becomes available to maintain a current evaluation landscape [Robo.tech, retrieved 2026].
Partially corroborated -- Product claims are sourced solely from the company's website; technical architecture and data source verification are not publicly available from independent third parties.
Market Research
Open sources The demand for AI to manage the exploding volume of scientific and commercial data in biopharma is not a speculative trend but a direct response to a quantifiable information overload that has outpaced human-led research processes. The market for Robo's specific offering,automated search and evaluation of external assets like drug candidates, technologies, and intellectual property,sits at the intersection of several larger, well-documented sectors: AI for drug discovery, competitive intelligence software, and scientific data analytics.
Public market sizing for this precise niche is not available, but analogous markets provide a sense of scale. The global AI in drug discovery market was valued at $1.2 billion in 2022 and is projected to reach $4.9 billion by 2028, growing at a compound annual growth rate (CAGR) of 26.5% [MarketsandMarkets, 2023]. Similarly, the broader life science analytics market is forecast to exceed $42 billion by 2030 [Grand View Research, 2023]. These figures underscore the substantial budgets and growth trajectory of the industries Robo aims to serve, though its specific serviceable obtainable market (SOM) would be a fraction of these totals, focused on the upstream evaluation and sourcing workflow.
Key demand drivers are evident from both industry reports and the pain points Robo's website articulates. The volume of biomedical literature and clinical trial data continues to grow exponentially, making manual review impractical. Concurrently, biopharma firms face intense pressure to replenish pipelines and identify external innovation efficiently, as internal R&D productivity has declined. This creates a tailwind for tools that promise to reduce search costs, accelerate due diligence, and mitigate the risk of missed opportunities. The shift towards more open innovation models and increased licensing activity further amplifies the need for systematic external asset evaluation.
Regulatory and macro forces present a mixed picture. On one hand, regulatory bodies like the FDA are increasingly accepting of real-world evidence and AI-derived insights in submissions, which could encourage adoption of data-intensive platforms [FDA, 2023]. On the other, data privacy regulations (e.g., GDPR, HIPAA) and concerns over intellectual property when using third-party AI tools could impose adoption friction. The primary competitive pressure may not come from direct substitutes but from internal builds or the expansion of general-purpose enterprise search platforms into the life sciences domain, though these often lack the domain-specific tuning and evaluation rigor Robo claims.
AI in Drug Discovery Market 2022 | 1.2 | $B
AI in Drug Discovery Market 2028 | 4.9 | $B
Life Science Analytics Market 2030 | 42 | $B
The projected growth rates for adjacent markets, particularly AI in drug discovery, indicate strong underlying tailwinds. However, Robo's success will depend on capturing a segment of this spend specifically allocated to the pre-deal evaluation and sourcing process, a narrower wedge than full-cycle discovery platforms.
Partially corroborated -- Market sizing is based on analogous, published third-party reports for adjacent sectors; specific TAM for complex asset search is not publicly defined.
Competition and Substitutes
Reported and inferred Robo's competitive position is defined by its narrow focus on automating the front-end of biopharma business development, a niche that sits between broad scientific AI platforms and manual research services.
The company's direct competitors are those offering AI tools for scientific literature and data analysis, though their core applications often differ. The competitive map segments into three layers: established AI-for-science platforms, specialized asset evaluation tools, and adjacent substitutes like consulting and internal teams.
Robo (Subject) | 1 | Positioning Score
Causaly | 3 | Positioning Score
Owkin | 3 | Positioning Score
BenchSci | 2 | Positioning Score
Arctoris | 1 | Positioning Score
The chart scores relative positioning on a 1-3 scale (1=narrow focus, 3=broad platform) based on public descriptions, illustrating Robo's concentrated wedge versus more diversified incumbents.
- Established AI-for-Science Platforms. Companies like Causaly and Owkin operate at a larger scale, building foundational AI models to uncover biomedical insights from vast datasets. Their positioning is broader, often targeting drug discovery and target identification directly for R&D teams [CB Insights]. This creates a flanking risk; if these platforms add a dedicated business development module, they could use their existing enterprise contracts and data scale.
- Specialized Evaluation & Lab Tools. Competitors such as BenchSci (AI for antibody search) and Arctoris (automated lab experimentation) address specific, technical workflows within the R&D value chain [Tracxn]. Their focus is deeper but different, making them indirect competitors for budget and attention rather than a direct substitute for asset search.
- Adjacent Substitutes. The most significant competitive pressure comes from non-software alternatives: internal analyst teams, legacy database subscriptions (e.g., Citeline, GlobalData), and boutique consulting firms. These represent the entrenched, high-cost workflows Robo aims to displace, and their persistence is the primary market adoption hurdle.
Robo's claimed defensible edge rests on its integrated workflow,combining natural-language query, multi-source search, and custom scoring into a single automated process,as described on its website [robo.tech, retrieved 2026]. This end-to-end automation for a specific user persona (business development, licensing) is its current wedge. The durability of this edge is perishable, however, as it depends on execution speed and data connectivity rather than proprietary, non-replicable technology. A competitor with greater resources could assemble a similar agentic workflow if the market signal proves strong.
The company is most exposed on two fronts. First, it lacks the deep scientific validation and published research that bolster the credibility of platforms like Owkin with pharmaceutical partners. Second, its distribution is unproven against the entrenched sales channels of large database incumbents, which have long-term contracts and dedicated relationship managers. Robo's website-led, "Book a Demo" go-to-market motion is untested against these forces.
A plausible 18-month scenario hinges on market education and execution speed. If Robo can secure a handful of flagship enterprise deployments and demonstrate clear ROI in shortening deal-sourcing cycles, it becomes an attractive acquisition target for a larger data or workflow platform looking to enter this niche. In this scenario, a "winner" could be a company like Tempus Ldn, which is expanding from oncology data into broader life sciences tools and might seek such automation capabilities. Conversely, if adoption is slow and a platform like Causaly launches a competing module first, Robo becomes the "loser," facing commoditization as a feature rather than a standalone product. The next year will likely determine whether this niche is large enough to support a dedicated vendor.
Partially corroborated -- Competitor identification is sourced from aggregated databases; precise positioning and differentiation are inferred from public company descriptions.
Opportunity
Open sources The prize for Robo is the automation of a multi-billion-dollar, high-stakes decision-making process in biopharma, where speed and accuracy in identifying external assets directly translate to pipeline value and competitive advantage.
The headline opportunity is for Robo to become the de facto operating system for external innovation in biopharma, a category-defining platform that moves beyond static databases and generic search tools. The company's own materials position it as an "end-to-end automation" tool for "nuanced, mission-critical research," a claim that, if validated, addresses a clear pain point in an industry where business development and licensing teams are resource-constrained [Robo.tech, retrieved 2026]. The outcome is reachable not because of a technological breakthrough in AI alone, but because of the specific wedge: automating the complex, criteria-heavy evaluation process that currently relies on manual PhD-level analysis. By converting natural language mandates into tailored AI agents that scour over 100 million primary sources, Robo is targeting the workflow itself, which is a more defensible position than simply offering another data aggregator.
Growth would likely follow one of several concrete paths, each requiring a distinct catalyst to move from early adoption to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Enterprise Standard | Robo becomes a mandated workflow tool for business development at top-20 pharma, displacing internal manual processes and legacy database subscriptions. | A marquee enterprise deal with a top-tier pharmaceutical company is publicly announced, serving as a category-tipping reference customer. | The product's stated focus on "enterprise-grade AI" and PhD-level rigor is tailored for this exact buyer [Robo.tech, retrieved 2026]. Competitors like Causaly and BenchSci have established enterprise traction in adjacent areas of research, validating the market's willingness to adopt AI tools [CB Insights]. |
| Platform Expansion | The core search and evaluation engine is productized as an API, enabling other life sciences software vendors (e.g., clinical trial platforms, data rooms) to embed its capabilities. | Robo launches a documented, self-serve API for developers, partnered with an initial integration into a well-known platform like Veeva or Medidata. | The company's architecture, built on autonomous AI agents, is inherently modular. A shift from a direct sales motion to a platform-plus-API model is a common scaling path for B2B AI infrastructure companies once a core workflow is proven. |
Compounding for Robo would manifest primarily as a data and feedback flywheel. Each enterprise deployment would generate proprietary search queries, evaluation criteria, and user refinement feedback. This dataset, which reflects the nuanced priorities and decision-making patterns of top-tier biopharma teams, could be used to further train and specialize the AI agents, improving result relevance for all customers. The company claims user feedback is "incorporated instantly, sharpening the AI agents," which is a direct description of this learning loop [Robo.tech, retrieved 2026]. Over time, this creates a data moat: the system becomes increasingly aligned with industry-specific evaluation heuristics that are difficult for a new entrant to replicate without similar depth of enterprise usage.
For a sense of the size of the win, consider the valuation of public and private peers in the broader life sciences AI and data ecosystem. Owkin, a competitor focused on AI for drug discovery and biomarker identification, reached a valuation of approximately $1.8 billion following its Series C round in 2023 [CB Insights, 2023]. Tempus Labs, which provides AI-powered precision medicine data, has been valued in the multi-billions. While Robo's focus is narrower, a successful execution of the Enterprise Standard scenario, capturing a material portion of the external asset evaluation workflow for large pharma, could support a valuation in the high hundreds of millions to low billions (scenario, not a forecast). This outcome is contingent on demonstrating that its automation materially accelerates deal sourcing or improves decision quality, thereby commanding a premium price point commensurate with the value of a pharmaceutical pipeline opportunity.
Partially corroborated -- The core product claims and opportunity framing are sourced directly from the company's website. The plausibility of growth scenarios is inferred from the product's stated focus and the established market for AI in biopharma, with competitor traction serving as indirect corroboration. No public evidence yet confirms commercial traction or a specific catalyst event.
Sources
Open sources
[Robo.tech, retrieved 2026] Robo - Complex Asset Search & Evaluation on Autopilot | https://robo.tech/
[LinkedIn, retrieved 2026] Robo | LinkedIn | https://www.linkedin.com/company/roboresearch
[Tracxn, retrieved 2026] Robo - 2026 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/robo/__qIt75OzG-4DJnWbb459c-fGD7tedFOloFo9_nr0JsAg#founders-and-board-of-directors
[CB Insights, retrieved 2026] Robo CEO, Founder, Key Executive Team, Board of Directors & Employees | https://www.cbinsights.com/company/robo/people
[LinkedIn: Braydon Moreno, retrieved 2026] Braydon Moreno - Boxlight | LinkedIn | https://www.linkedin.com/in/braydonmoreno/
[LinkedIn: David Dimeo, retrieved 2026] David DiMeo - Co-Founder - Robo Retail, LLC | LinkedIn | https://www.linkedin.com/in/david-dimeo-2a11458/
[Crunchbase, retrieved 2026] Braydon Moreno - Crunchbase | https://www.crunchbase.com/person/braydon-moreno
[ideamensch.com, retrieved 2026] Braydon Moreno - ideamensch | https://ideamensch.com/braydon-moreno/
[The Org: David DiMeo, retrieved 2026] David DiMeo - The Org | https://theorg.com/org/robo-retail/org-chart/david-dimeo
[Success.ai: David Dimeo, retrieved 2026] David Dimeo - Success.ai | https://success.ai/david-dimeo
[Robotics Tomorrow, January 2025] RoboForce Secures $10M Early Stage Funding for AI-Powered Robo-Labor With Initial Focus in Solar, Space Industries | https://www.roboticstomorrow.com/news/2025/01/06/roboforce-secures-10m-early-stage-funding-for-ai-powered-robo-labor-with-initial-focus-in-solar-space-industries/23801/
[MarketsandMarkets, 2023] AI in Drug Discovery Market - MarketsandMarkets Report | https://www.marketsandmarkets.com/Market-Reports/ai-in-drug-discovery-market-151193446.html
[Grand View Research, 2023] Life Science Analytics Market Size, Share & Trends Analysis Report - Grand View Research | https://www.grandviewresearch.com/industry-analysis/life-science-analytics-market
[FDA, 2023] FDA's Real-World Evidence Program | https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
Articles about Robo
- Robo's AI Agents Search 100 Million Sources for the Biopharma Scout — The Santa Monica startup automates complex asset evaluation for drug developers, but its founders' other ventures and a crowded competitor field raise questions.